Breaking News

Janssen, Vertex to Collaborate on Flu Treatment

Janssen and Vertex will work together to develop, make and commercialize VX-787, a medication designed to stop replication of Influenza A virus, which is now in Phase II trials.

Janssen Pharmaceuticals, Inc. (Janssen) will collaborate with Vertex Pharmaceuticals on worldwide development, manufacturing and commercialization of VX-787, an investigational medicine now in Phase II development for the treatment of influenza A. The medication is designed to inhibit replication of the influenza A virus, including recent H1 (pandemic) and H5 (avian) influenza strains, based on in-vitro data. The drug would be offered to fight resistance to existing antivirals for influenza. &...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters